%0 Journal Article %T Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Alhanafy, Alshimaa Mahmoud %A Zanaty, Fouad %A Ibrahem, Reda %A Omar, Suzan %D 2018 %\ 04/01/2018 %V 19 %N 4 %P 1113-1118 %! Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume %K Disease volume %K Metastatic prostate cancer %K survival %R 10.22034/APJCP.2018.19.4.1113 %X Background and Aim: The optimal management of metastatic hormone-sensitive prostate cancer has beencontroversial in recent years with introduction of upfront chemohormonal treatment based on results of several Westernstudies. This changing landscape has renewed interest in the concept “disease volume”, the focus of the present studyis the Egyptian patients. Methods: Patients with hormone sensitive metastatic prostate cancer presenting at MenoufiaUniversity Hospital, Egypt, during the period from June 2013 to May 2016, were enrolled. All received hormonaltreatment. Radiologic images were evaluated and patients were stratified according to their disease volume into high orlow, other clinical and pathological data that could affect survival also being collected and analyzed. Results: A totalof 128 patients were included, with a median age of 70 years (53.9% ≥70). About 46% had co-morbidities, 62% havinghigh volume disease. During the median follow up period of 28 months about half of the patients progressed and onethird received chemotherapy. On univariate analysis, disease volume, performance status (PS), prostate specific antigenlevel (PSA) and presence of pain at presentation were identified as factors influencing overall survival. Multivariateanalysis revealed the independent predictor factors for survival to be PS, PSA and disease volume. The median overallsurvival with 27 months was high volume versus 49 with low volume disease (hazard ratio 2.1; 95% CI 1.2 - 4.4;P=0.02). Median progression free survival was 19 months in the high volume, as compared with 48 months in the lowvolume disease patients (hazard ratio, 2.44; 95% CI, 1.42 – 7.4; P=0.009). Conclusions: Disease volume is a reliablepredictor of survival which should be incorporated with other important factors as; patient performance status andcomorbidities in treatment decision-making. %U https://journal.waocp.org/article_59851_8f664414bedc3a971ae633773f69b701.pdf